CEPI partners with Japan's NEC Group to develop artificial intelligence-designed broadly protective betacoronavirus vaccine
08 Apr 2022
April 8, 2022; OSLO, Norway/ TOKYO, Japan: CEPI, the Coalition for Epidemic Preparedness Innovations, and NEC Corporation (NEC: TSE: 6701) today announced the latest funding award under CEPI’s US$200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2 variants and other betacoronaviruses. CEPI will provide seed funding of up to US$4.8m to NEC OncoImmunity AS (NOI), a Norway-based subsidiary of NEC, which specializes in artificial intelligence-driven biotechnology, to support the initial development of broadly protective betacoronavirus vaccine candidates.
NEC, through NOI, will lead a research consortium including the European Vaccine Initiative (EVI) and Oslo University Hospital to deliver a project which aims to establish preclinical proof of concept for a vaccine based on mRNA technology that protects against a broad range of betacoronaviruses. NEC will apply its experience and capabilities in artificial intelligence-powered design of immunogens to identify novel vaccine antigens with broad reactivity against betacoronaviruses. The lead antigens will be selected iteratively and validated in preclinical studies against known betacoronaviruses that already pose a significant epidemic or pandemic risk, such as SARS-CoV, SARS-CoV-2 & MERS-CoV.
If this innovative approach is proven to be successful, it may also be applicable for developing vaccines against other pathogens in the CEPI portfolio, including ‘Disease X’ – unknown pathogens with pandemic potential that have yet to emerge.
CEPI is committed to the principle of equitable access to the vaccines it funds. Under the terms of the funding agreement, NEC has committed to achieving equitable access to the outputs of this project, in line with CEPI’s Equitable Access Policy.
“
Coronaviruses have now proven their pandemic potential with devastating consequences, and COVID-19 won’t be the last coronavirus to threaten humanity. That’s why CEPI’s ambitious programme to develop globally accessible vaccines that protect against a broad range of coronaviruses – before those pathogens emerge - is critical to global health security.
“
Japan has a proud history of global health leadership and has long championed the role of research and development in fighting emerging infectious diseases, including the Government of Japan’s critical role as a founding member and major investor in CEPI. I am delighted that CEPI will partner with NEC Corporation – our first collaboration with Japanese industry - to advance this innovative, AI-driven approach to vaccine design, which could help take the threat of coronaviruses off the table if it is proven to be successful.
Dr. Richard Hatchett
Chief Executive Officer, CEPI
“
Dealing with the challenges caused by the COVID-19 pandemic has taken a significant toll on people’s lives. The hard lessons will remain with us for decades and it is crucial that we arm ourselves against future invisible enemies. We are elated to partner with CEPI on this mission to develop vaccines against coronaviruses using our advanced AI technologies. While this partnership is a recognition of NEC’s expertise and growing contribution to healthcare, it also acknowledges Japan’s leadership in advancing drug development through breakthrough technologies. We will continue to mobilize the resources of the NEC Group for this collaborative effort to ensure global health security.
Nobuhiro Endo
Chairman of the Board, NEC Corporation
“
We are extremely honored to have CEPI place its trust in the quality of our technology and the expertise of our scientific teams. Our experience with COVID-19 has taught us that an ideal vaccine must remain robust against an ever-evolving viral landscape. Our AI will assess viral regions that do not mutate rapidly and are shared among SARS, SARS-CoV-2, MERS-CoV and other known betacoronaviruses. I am confident that our unique approach in identifying and selecting antigens that could elicit broader cytotoxic T cell and antibody responses is well positioned to help create broadly protective betacoronavirus vaccines that could protect the global population against multiple betacoronavirus threats on a long-term basis.
Richard Stratford Ph.D
Chief Executive Officer, NEC OncoImmunity AS
“
We are proud to see NEC become the first Japanese company to participate in CEPI's activities for promoting vaccine development in response to and in preparation for potential pandemics, which is a common issue for all humankind. In February 2022, the Government of Japan announced a new contribution of US$300 million to CEPI over the next five years, and has been actively supporting the development of vaccines in the international community. We expect that NEC will contribute to global health with the development of next-generation vaccines using the world's most advanced AI.
Tagaya Nobunao
Senior Assistant Minister for International Affairs, Ministry of Health, Labour and Welfare, Japan
“
For the Japanese vaccine industry, NEC's participation in this global challenge is great news. We look forward to it contributing to the early countermeasures against pandemics by advancing the speedy development of safer and more effective vaccines with the new science approach of utilizing AI.
Ken Ishii
Professor, Institute of Medical Science, University of Tokyo
Strengthening our defenses against coronaviruses
Through COVID-19, coronaviruses have now demonstrated their devastating pandemic potential. The emergence of a coronavirus combining the transmissibility of COVID-19 with the lethality of SARS or MERS would be catastrophic, so developing vaccines that provide broad protection against the whole betacoronavirus genus is therefore vital to our global health security. CEPI is working closely with partners to advance work in this area as quickly as possible.
The award announced today is the eighth programme to be funded by CEPI to advance the development of vaccines that provide broad protection against SARS-CoV-2 variants and other betacoronaviruses. This work forms an important part of CEPI’s next 5-year plan, published in March 2021, which aims to reduce or even eliminate the future risk of pandemics and epidemics.
[1] Betacoronaviruses are types of coronavirus that cause Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), which have been responsible for major epidemics in Asia and the Middle East in recent years, and also SARS-CoV-2, the virus responsible for the ongoing COVID-19 pandemic.
–ENDS—
Notes to Editors
Including today’s announcement, CEPI has to date announced funding for eight programmes to advance the development of vaccines that could provide broad protection against SARS-CoV-2 variants and other betacoronaviruses:
–MigVax Ltd – funding of US$4.3m to MigVax Ltd to support the initial development of a new orally administered subunit vaccine tablet that could offer broad protection against SARS-CoV-2 variants.
–University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO) – funding of US$5m to support the initial development of a new vaccine based on VIDO’s novel protein subunit technology that could offer broad protection against SARS-CoV-2 variants.
–Affinivax – funding of up to $4.5m to support the initial development of a vaccine candidate based on Affinivax’s MAPS platform that could offer broad protection against SARS-CoV-2 variants.
–SK bioscience – funding of up to US$50m to support the development of a vaccine candidate based on SK’s nanoparticle vaccine platform to elicit immune responses that could protect against variants of both SARS-CoV, SARS-CoV-2, and other
–Translational Health Science and Technology Institute (THSTI) and Panacea Biotec – funding of up to US12.5m to support the development of multi-epitope, nanoparticle-based vaccine candidates that could provide broad protection against SARS-CoV-2 variants and other Betacoronaviruses.
–BioNet – funding of up to US$16.9m to advance the development of a novel mRNA-based vaccine that could offer broad protection against SARS-CoV-2 variants.
–DIOSynVax – funding of up to US$42m to support the development of a broadly protective Betacoronavirus vaccine using mRNA platform technology.
-NEC Corporation – funding of up to US$4.8m to support the initial development of an AI-designed vaccine based on mRNA technology that protects against a broad range of betacoronaviruses.
About CEPI
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI’s work focused on developing vaccines against the Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. It has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X).
During the current pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale and access. These programmes leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19, as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation of these vaccines worldwide through COVAX.
CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at http://endpandemics.cepi.net.
Follow our news page for the latest updates. Follow us via @CEPIvaccines, @DrRHatchett, and on LinkedIn.
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.
About NEC OncoImmunity AS
NEC OncoImmunity AS is an AI driven biotechnology company that has developed proprietary machine learning-based software which addresses the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy, in addition to infectious disease vaccines. The AI technology can be used to identify optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable timeframe, and also facilitate effective patient selection for cancer immunotherapy. For more information, visit NEC OncoImmunity AS at http://www.oncoimmunity.com/
Media contacts
CEPI
Email: [email protected]
Phone: +44 7387 055214
NEC
Email: [email protected]
